Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,209.01
(
1.02%
)
US TECH 100
26,729.60
(
1.01%
)
Dow Jones
49,652.14
(
1.62%
)
Brent Oil
110.33
(
-1.82%
)
Bitcoin
76,252.79
(
0.63%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: cheynew post# 259864

Saturday, 03/26/2016 12:48:46 PM

Saturday, March 26, 2016 12:48:46 PM

Post# of 347009
Was holding MEDX then, there is no similarity between MEDX and PPHM whatsoever. MEDX was in partnership with BMY, JNJ, MRK etc at that time already, market cap around $1.3B, around $8.5/share. Ipilimumab was in 2 ph3 melanoma trials which lasted forever. BMY acquired at 90% premium for $2.4B. Remember that was in 2009 just after financial crisis.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote